Filing Flows › Novartis AG (NVS) › Kesimpta revenue
Novartis AG (NVS) Kesimpta revenue by quarter
Novartis AG's Kesimpta revenue was $2.7B in Q3 2026 (third quarter 2026), -9% from Q4 2025. Over the last 3 quarters it ranged from $2.1B (Q3 2025) to $2.9B (Q4 2025).
| Quarter | Kesimpta revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.7B | -9% | +26% |
| Q4 2025 | $2.9B | +38% | — |
| Q3 2025 | $2.1B | — | — |
Q3 2026 at a glance
Novartis AG, Q3 2026: revenue $14.5B (+4% year over year), operating margin 12.7%, net earnings $1.2B, operating cash flow $5.5B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novartis AG's Kesimpta revenue?
Novartis AG's Kesimpta revenue was $2.7B in Q3 2026 (third quarter 2026), -9% from Q4 2025.
How has Novartis AG's Kesimpta revenue changed?
Over the last 3 quarters it ranged from $2.1B (Q3 2025) to $2.9B (Q4 2025).